News headlines about Ophthotech (NASDAQ:OPHT) have been trending positive this week, according to Accern Sentiment Analysis. The research firm identifies positive and negative press coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Ophthotech earned a media sentiment score of 0.29 on Accern’s scale. Accern also assigned news stories about the biopharmaceutical company an impact score of 44.903702513214 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
Ophthotech (NASDAQ:OPHT) traded down $0.06 during trading hours on Friday, reaching $2.79. The company’s stock had a trading volume of 372,013 shares, compared to its average volume of 414,528. The stock has a market capitalization of $98.43, a price-to-earnings ratio of 1.79 and a beta of 1.43. Ophthotech has a one year low of $2.24 and a one year high of $4.81.
Ophthotech (NASDAQ:OPHT) last posted its quarterly earnings results on Wednesday, November 8th. The biopharmaceutical company reported $5.25 EPS for the quarter, topping the Zacks’ consensus estimate of $4.38 by $0.87. Ophthotech had a negative return on equity of 69.40% and a net margin of 26.69%. The business had revenue of $206.65 million during the quarter, compared to the consensus estimate of $185.00 million. equities research analysts expect that Ophthotech will post 2.88 EPS for the current fiscal year.
A number of equities research analysts have commented on OPHT shares. Zacks Investment Research upgraded Ophthotech from a “hold” rating to a “strong-buy” rating and set a $3.25 target price on the stock in a report on Monday, November 13th. ValuEngine lowered Ophthotech from a “buy” rating to a “hold” rating in a research note on Sunday, December 31st. Finally, TheStreet raised Ophthotech from an “e+” rating to a “c” rating in a research report on Thursday, November 30th.
In related news, CEO Glenn Sblendorio sold 8,089 shares of the business’s stock in a transaction that occurred on Tuesday, January 2nd. The stock was sold at an average price of $3.19, for a total transaction of $25,803.91. Following the sale, the chief executive officer now owns 44,584 shares of the company’s stock, valued at $142,222.96. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider David R. Guyer sold 16,520 shares of the business’s stock in a transaction that occurred on Tuesday, January 2nd. The stock was sold at an average price of $3.19, for a total value of $52,698.80. Following the sale, the insider now directly owns 50,494 shares in the company, valued at approximately $161,075.86. The disclosure for this sale can be found here. Insiders sold 34,971 shares of company stock worth $111,481 in the last three months. 2.00% of the stock is currently owned by corporate insiders.
Ophthotech Corporation is a biopharmaceutical company. The Company is engaged in the development of therapeutics to treat ophthalmic diseases, with a focus on diseases of the back of the eye. Its primary focus is developing therapeutics for age-related macular degeneration (AMD), which is a disorder of the central portion of the retina, known as the macula, that may result in blindness.
Receive News & Ratings for Ophthotech Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Ophthotech and related companies with MarketBeat.com’s FREE daily email newsletter.